Trial Profile

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 29 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vatiquinone (Primary)
Indications Epilepsy; Mitochondrial disorders
Focus Registrational; Therapeutic Use
Acronyms MIT-E
Sponsors PTC Therapeutics

Most Recent Events

27 Aug 2024 Status changed from completed to discontinued.
30 Jan 2024 This study has been discontinued in Poland, according to European Clinical Trials Database record.
24 Jan 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com